NEW DELHI – The World Health Organization (WHO) has pre-qualified Indian company Bharat Biotech International Ltd.'s Typbar TCV, its conjugate vaccine against typhoid fever. The pre-qualification paves the way for possible use in childhood immunization programs against typhoid in high-risk, endemic countries.
NEW DELHI – While the recent FDA approval for a biosimilar version of Roche Holding AG's cancer drug, Herceptin (trastuzumab), developed by Mylan NV and Indian company Biocon Ltd., was notable as the first biosimilar approved in the U.S. for the treatment of breast cancer or stomach cancer, the approval also gives a huge fillip to India's nascent and emerging biosimilars industry.
NEW DELHI – While the recent FDA approval for a biosimilar version of Roche Holding AG's cancer drug, Herceptin (trastuzumab), developed by Mylan NV and Indian company Biocon Ltd., was notable as the first biosimilar approved in the U.S. for the treatment of breast cancer or stomach cancer, the approval also gives a huge fillip to India's nascent and emerging biosimilars industry.
HYDERABAD, India – India's drug authority has granted approval to Mylan Inc.'s Indian arm to market its anti-tuberculosis drug delamanid developed specifically for treating multidrug-resistant tuberculosis (MDR TB). Meanwhile, the country is also actively exploring new entities to tackle the TB problem via public-private partnership.
NEW DELHI – India launched its first formal industry-academia mission to ramp up its biopharma development by promoting entrepreneurship and indigenous manufacturing to transform the country into a global hub for cutting-edge biotechnology R&D.
HYDERABAD, India – India’s drug authority has granted approval to Mylan Inc.’s Indian arm to market its anti-tuberculosis drug delamanid developed specifically for treating multidrug-resistant tuberculosis (MDR TB). Meanwhile, the country is also actively exploring new entities to tackle the TB problem via public-private partnership.
NEW DELHI – India launched its first formal industry-academia mission to ramp up its biopharma development by promoting entrepreneurship and indigenous manufacturing to transform the country into a global hub for cutting-edge biotechnology R&D.
NEW DELHI – India's national drug regulator has stopped individual state drug regulators from independently issuing manufacturing licenses to companies that have not acquired prior manufacturing approval from the Drug Controller General of India.
NEW DELHI – India's national drug regulator has stopped individual state drug regulators from independently issuing manufacturing licenses to companies that have not acquired prior manufacturing approval from the Drug Controller General of India.
